DOCSLIB.ORG

New Developments in Lymphoma Therapy Sven De Vos, MD, Phd UCLA Lymphoma Program Los Angeles

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
New Developments in Lymphoma Therapy Sven De Vos, MD, Phd UCLA Lymphoma Program Los Angeles Arrowhead 2018 New Developments in Lymphoma Therapy Sven de Vos, MD, PhD UCLA Lymphoma Program Los Angeles SdV Sept 2018 Conflict of Interest • Salary: none • Royalty: none • Receipt of Intellectual Property Rights/Patent Holder: none • Consulting Fees (e.g., advisory boards): Verastem • Fees for Non-CME Services Received Directly from a Commercial Interest or their Agents (e.g., speakers’ bureau): none • Contracted Research: none • Ownership Interest (stocks, stock options or other ownership interest excluding diversified mutual funds): none • Other: none SdV Sept 2018 DLBCL Advancing Treatment in the Genomic Era (Lenz et al. JCO, 2007, Lam et al. Clin Can Res. 2005, Hans et al. Blood. 2004, Rosenwald et al. NEJM. 2002, Ngo et.al Nature 2006, Davis J. Exp Med 2001) Double-Hit vs. Double-Expresser DLBCL SdV Sept 2018 (Dunleavy et al., ICML Lugano, 2015) 2016 Revision of the WHO classification: New Category High-grade B-cell lymphoma (HGBL HGBL HGBL with MYC and BCL2 and/or BCL6 rearrangements HGBL not otherwise specified Frequency of MYC/BCL2 DHL is approximately 10% of all DLBCL Patients with HGBL should be enrolled into clinical trials SdV Sept 2018 (Li et al., Expert Review of Hematology 2018; 11: 637–648) Genetically-Defined DLBCL Subsets Arise By Distinct Pathogenetic Mechanisms and Predict Outcome . Comprehensive analysis of DLBCL with whole exome sequencing (WES) • mutations, copy number alterations (CNAs), structural variants (SVs) . N=304 newly Dx DLBCL (R-CHOP) • Total of 158 SMGs (98), CNAs and SVs • Most exome mutations caused by spontaneous deamination at CpGs (c/w aging) • Most frequently rearranged genes: IGH (40%), BCL2 (21%), BCL6 (19%), MYC (8%) • SMGs more likely to reside within focal CNAs, c/w multiple mechanisms • Individual DLBCLs had a median of 17 genetic drivers!! . Integrated clustering approach: 5 genetically distinct DLBCL subtypes . ABC, good risk genetic features of possibly marginal zone origin . ABC, poor risk frequent BCL2 gain and concordant MYD88L265P/CD79B mut . GCB, good risk pathway alterations in BCR/PI3K, JAK/STAT and BRAF and multiple histones . GCB, poor risk BCL2 SVs, alterations of PTEN and epigenetic enzymes . COO-independent biallelic inactivation of TP53, 9p21.3/CDKN2A and associated genomic instability SdV Sept 2018 (Chapuy et al., ASH 2017, abstract # 38) Chromosomal rearrangements in primary DLBCLs - BCL2, BCL6, and MYC - SdV Sept 2018 (Chapuy et al., Nature Med 2018, 24: 679- 690 ) Identification of groups of tumors with coordinate genetic signatures Cluster 1 ABC - good risk Cluster 2 COO-independent biallelic TP53 inactivation Cluster 3 GCB - poor risk Cluster 4 GCB - good risk Cluster 5 ABC - poor risk SdV Sept 2018 (Chapuy et al., Nature Med 2018, 24: 679- 690 ) Genetics and Pathogenesis of DLBCL . Exome and transcriptome sequencing, array-based DNA copy-number analysis, and targeted amplicon resequencing . N=574 newly Dx DLBCL . Four prominent genetic subtypes in DLBCL . MCD MYD88L265P and CD79B mutations “chronic active” . BN2 BCL6 fusions and NOTCH2 mutations B-cell receptor signaling . N1 NOTCH1 mutations . EZB EZH2 mutations and BCL2 translocations OS SdV Sept 2018 (Schmitz et al., NEJM 2018, 378:1396-1407) Genetic Aberrations Targeting Oncogenic Signaling Pathways in DLBCL SdV Sept 2018 (Schmitz et al., NEJM 2018, 378:1396-1407) Moving forward… . More global approach to DLBCL classification, focusing much more on pathways than single gene abnormalities (Schmitz et al. and Chapuy et al.) . Complexity of DLBCLs, median of 17 different genetic alterations per tumor . Key genetic features included mutations, SCNAs, and SVs . All three types of alterations needed to capture disease heterogeneity and outcome differences . The new genetic subtypes will guide the development of rational single-agent and combination therapies in patients with the greatest need SdV Sept 2018 Rand., double-blind, placebo-controlled ph3 study of Ibrutinib in comb. BTK with R-CHOP in newly diagnosed non-GCB DLBCL (PHOENIX) ACCURAL COMPLETE Sub-typing Regimen GCB DLBCL Ø Newly Central R-CHOP diagnosed Lab 48 hrs DLBCL Non-GCB Randomized DLBCL R-CHOP + Ibrutinib . N=800 non-GCB DLBCL . Primary endpoint: EFS 6 cycles Q 3weeks . Study aims at improving Ibrutinib: 560 mg QD the cure rate by 10% Press release (July 11, 2108) . Missing the primary endpoint. No improved EFS. “Clinically meaningful improvements were observed in a patient subpopulation that warrant further analysis.” Update at ASH 2018 SdV Sept 2018 (Clinicaltrials.gov: NCT01855750) Synthetic Lethal Therapy of ABC DLBCL Rationale for Ibrutinib + Lenalidomide combination SdV Sept 2018 (Yang et al., Cancer Cell 2012, 21:723) A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (PCYC-1123-CA) UCLA trial open Chemotherapy free novel combination Phase 1b: • Determine MTD • N ~ 48 patients • All types of rel/refr DLBCL Phase 2: • Evaluate efficacy, identify signaling pathways or Ibrutinib + Lenalidomide biomarkers that predict response to Ibrutinib • N = 150 patients Randomization • Rel/refr de novo non-CGB DLBCL 1:1 Ibrutinib + Lenalidomide • s/p ASCT or not candidate for ASCT + • No transformed DLBCL Rituximab • No CNS involvement Ibrutinib daily Lenalidomide days 1-21 on 28 day cylce Rituximab day 1 per cycle (cycle 1-6) Update at ASH 2018 SdV Sept 2018 LEN R2CHOP in untreated DLBCL compared to R-CHOP R-CHOP R2-CHOP R-CHOP R2-CHOP (Grzegorz S. Nowakowski et al. JCO 2015;33:251-257) ROBUST (NCT02285062) . Lenalidomide + R-CHOP vs Placebo Plus R-CHOP in 1st line ABC-DLBCL, Phase 3, double-blind, placebo-controlled (completed enrollment) REMARC . Lenalidomide vs Placebo in elderly patients with DLBCL. No survival benefit. SdV Sept 2018 A Phase II, Single-Arm, Open-Label, Multicenter Study to Evaluate the CD19 Safety and Efficacy of Lenalidomide Combined with MOR00208 in Patients with Relapsed or Refractory DLBCL TRIO-US trial completed enrolment Inclusion: Fc-engineered, humanized, CD19 antibody • DLBCL, Transformed DLBCL • ineligible for HDC and ASCT MOR00208 (anti CD19) + MOR00208: Lenalidomide • Dose: 12 mg/kg, 28-day cycles. • Study Duration • Cycles 1-3: Day 1, Day 8, Day 15 and Day 22 • Thereafter bi-weekly • MOR00208 for up to 24 months • LEN up to 12 months Lenalidomide: • 25 mg oral LEN daily on Days 1–21 of each cycle • LEN may be modified in a de-escalating fashion Oct. 23 2017: Results: FDA Breakthrough Therapy • 31 of 80 planned pts Designation for MOR208 in • ORR 58% with CR 27% R/R DLBCL in combination • median follow-up 3.3 months with Lenalidomide • AE > gr3 neutropenia (26%), thrombocytopenia (6%), Update at ASH 2018 infections (10%), rashes (6%) SdV Sept 2018 (Maddocks, et al., ASCO 2017; # 7514) CC-122 CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL Model of CC-122 co-stimulation of T cells and tumoricidal activity . CC-122 is a novel agent for DLBCL with antitumor and immunomodulatory activity . Binds CRBN and degrades Aiolos and Ikaros resulting in a mimicry of IFN signaling and apoptosis in DLBCL . Cell-of-origin independent anti-lymphoma activity SdV Sept 2018 (Hagner et al., Blood 2015; 126: 779-789) Study of Safety and Efficacy of CC-122 Combined With RCHOP for CC-122 Newly-diagnosed DLBCL With Poor Risk Factors TRIO-US trial planned Newly Both diagnosed subtypes R-CHOP DLBCL eligible + CC-122 Poor-risk GCB Non-GCB avadomide IPI ≥ 3 DLBCL DLBCL 6 cycles Q 3 Phase 1 • Safety and phase 2 dose Phase 2 • ORR when adding avadomide (CC-122) to R-CHOP-21 Principal Investigator: Sven de Vos, MD SdV Sept 2018 (Clinicaltrials.gov: NCT03283202) Bcl-2 Phase Ib/II – CAVALLI: R/G-CHOP + venetoclax TRIO-US trial completed enrolment Dose escalation cohorts Phase II cohort Arm A R-CHOP + VEN N~160–200 R-CHOP + VEN N=12–24 Two major goals: Arm B G-CHOP + VEN N=12–24 1. DLBCL Phase III planning 2. Focus on Bcl-2/MYC DE • Patients: – Escalation: mixed histology NHL – Phase II: previously untreated DLBCL, IPI 2–5 • Cohorts: R-CHOP or G-CHOP + venetoclax designed at 4 dose escalation levels: 200mg, 400mg, 600mg, 800mg – 800mg in Phase II • Phase II: R-CHOP arm aims to enroll: – 50+ DE patients – ~40 patients in each additional subset (subgroup-specific efficacy data for Phase III planning) – Primary efficacy endpoint: PET-CR Update at ASH 2018 • Historical control: R-CHOP GOYA data SdV Sept 2018 (Clinicaltrials.gov: NCT02055820) Bcl-2 Phase Ib/II – CAVALLI: R/G-CHOP + venetoclax - report on phase 1 - SdV Sept 2018 (Zelenetz, et al., ASH 2016) Bcl-2 Phase Ib/II – CAVALLI: R/G-CHOP + venetoclax - report on phase 1 - DLBCL patients: biomarker expression and PET response (R-CHOP and G-CHOP arms combined) Biomarker expression (IHC) and PET/CT (Lugano 2014 criteria by investigator) response Double Double Data Bcl-2 – /MYC+ Total=15 expressor negative unavailable n=4 n (%) n=8 n=1 n=2 CR 7 3 1 2 13 (87%) PR 0 0 0 0 0 PD 1† 1‡ 0 0 2 (13%) Summary of efficacy in front line 1L DLBCL • Two PDs: 1PD‡ on day 5, 1PD† at EOT (R-CHOP arm) SdV Sept 2018 (Zelenetz, et al., ASH 2016) CD79B Randomized phase 2 trial of polatuzumab vedotin with bendamustine and rituximab in relapsed/refractory FL and DLBCL SdV Sept 2018 (Sehn, et al., ASCO 2016) CD79B Randomized phase 2 trial of polatuzumab vedotin with bendamustine and rituximab in relapsed/refractory FL and DLBCL SdV Sept 2018 (Sehn, et al., ASCO 2016)
Load more

Recommended publications
  • Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
    Predictive QSAR tools to aid in early process development of monoclonal antibodies John Micael Andreas Karlberg Published work submitted to Newcastle University for the degree of Doctor of Philosophy in the School of Engineering November 2019 Abstract Monoclonal antibodies (mAbs) have become one of the fastest growing markets for diagnostic and therapeutic treatments over the last 30 years with a global sales revenue around $89 billion reported in 2017. A popular framework widely used in pharmaceutical industries for designing manufacturing processes for mAbs is Quality by Design (QbD) due to providing a structured and systematic approach in investigation and screening process parameters that might influence the product quality. However, due to the large number of product quality attributes (CQAs) and process parameters that exist in an mAb process platform, extensive investigation is needed to characterise their impact on the product quality which makes the process development costly and time consuming. There is thus an urgent need for methods and tools that can be used for early risk-based selection of critical product properties and process factors to reduce the number of potential factors that have to be investigated, thereby aiding in speeding up the process development and reduce costs. In this study, a framework for predictive model development based on Quantitative Structure- Activity Relationship (QSAR) modelling was developed to link structural features and properties of mAbs to Hydrophobic Interaction Chromatography (HIC) retention times and expressed mAb yield from HEK cells. Model development was based on a structured approach for incremental model refinement and evaluation that aided in increasing model performance until becoming acceptable in accordance to the OECD guidelines for QSAR models.
    [Show full text]
  • Ublituximab (TG-1101) in Combination with Umbralisib (TGR-1202) for Chronic Lymphocytic Leukaemia NIHRIO (HSRIC) ID: 12230 NICE ID: 9540
    NIHR Innovation Observatory Evidence Briefing: SEPTEMBER 2017 Ublituximab (TG-1101) in combination with umbralisib (TGR-1202) for chronic lymphocytic leukaemia NIHRIO (HSRIC) ID: 12230 NICE ID: 9540 LAY SUMMARY Chronic lymphocytic leukaemia is a type of blood cancer that develops inside the bone marrows. This produces abnormal types of white blood cells (lymphocytes) which do not function properly, hence, do not protect from infections the way they should do. Chronic types of leukaemia develop slowly over a long time. Symptoms of this cancer usually only develop at a later stage of the disease. They may include frequent infections, persistent tiredness, shortness of breath, pale skin, bleeding and bruising more easily and others. The cause of chronic lymphocytic leukaemia is not yet fully understood but risk factors may include age (older people), exposure to chemicals, family history, gender or ethnicity. Ublituximab in combination with umbralisib is under development for the treatment of chronic lymphocytic leukaemia and other types of blood cancers. They both act in different ways to suppress the production and growth of the abnormal lymphocytes caused by bindings to certain cells and proteins in the body that produces the cancer. If licensed, it will offer an additional treatment option for patients with chronic lymphocytic leukaemia. This briefing is based on information available at the time of research and a limited literature search. It is not intended to be a definitive statement on the safety, efficacy or effectiveness of the health technology covered and should not be used for commercial purposes or commissioning without additional information. This briefing presents independent research funded by the National Institute for Health Research (NIHR).
    [Show full text]
  • 2015 Post-ASH Report
    Datamonitor Healthcare Trialtrove Biomedtracker Pharma intelligence | Pharma intelligence | Pharma intelligence | 2015 Post-ASH Report RACHEL MEIGHAN-MANTHA Principal Analyst, Citeline JOSEPH HEDDEN Senior Analyst, Datamonitor Healthcare Summary Profiled themes at the 57th Annual Meeting and Exposition of the American Society of Hematology (ASH), held December 5-8, 2015, in Orlando, Florida, included Genomic Profiling and Chemical Biology, Genome Editing and Gene Therapy, Epigenetic Mechanisms, Immunologic Treatments, Stem Cell Biology and Regenerative Medicine and Preventing Venous Thromboembolic Disease. This report will mainly focus on the theme of Immunologic Treatments because of the importance and popularity of immunotherapies for many different hematological cancers. Also covered in this report are the results from pivotal trials presented at ASH, as well as highlights from other drugs/therapies of interest. In addition, we felt it was important to cover first-in-human trials since (hopefully) some of these drugs/therapies will be in pivotal trials in a few years. At the end of the report, we’ve included a section showcasing drugs that had top- line results presented at ASH, followed by a list of other data presentations supplied by BioMedTracker (BMT). Accompanying links to BioMedTracker events along with changes to the drugs’ likelihood of approval (LOA) are also provided throughout the report. Finally, additional supplemental material related to ASH is listed in the Appendix. 2 Datamonitor Healthcare Trialtrove Biomedtracker
    [Show full text]
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]
  • The Future of Antibodies As Cancer Drugs
    REVIEWS Drug Discovery Today Volume 17, Numbers 17/18 September 2012 The biopharmaceutical industry’s pipeline of anticancer antibodies includes 165 candidates with substantial diversity in composition, targets and mechanisms of action that hold promise to be the cancer drugs of the future. Reviews FOUNDATION REVIEW Foundation review: The future of antibodies as cancer drugs 1 2 Dr Janice Reichert Janice M. Reichert and Eugen Dhimolea is Research Assistant Professor at Tufts 1 Center for the Study of Drug Development, Tufts University School of Medicine, 75 Kneeland Street, University’s Center for the Study of Drug Development Suite 1100, Boston, MA 02111, USA 2 (CSDD). She is also Founder Department of Medical Oncology, Dana-Farber Cancer Institute/Harvard Medical School, 77 Louis Pasteur Ave., and Editor-in-Chief of mAbs, Harvard Institutes of Medicine, Room 309, Boston, MA 02215, USA a peer-reviewed, PubMed- indexed biomedical journal that focuses on topics relevant to antibody research Targeted therapeutics such as monoclonal antibodies (mAbs) have proven and development; President of the board of directors of The Antibody Society; and a member of the board successful as cancer drugs. To profile products that could be marketed in of the Peptide Therapeutics Foundation. At CSDD, the future, we examined the current commercial clinical pipeline of mAb Dr Reichert studies innovation in the pharmaceutical and biotechnology industries. Her work focuses on candidates for cancer. Our analysis revealed trends toward development of strategic analyses of investigational candidates and marketed products, with an emphasis on the clinical a variety of noncanonical mAbs, including antibody–drug conjugates development and approval of new therapeutics and (ADCs), bispecific antibodies, engineered antibodies and antibody vaccines.
    [Show full text]
  • 2017 Immuno-Oncology Medicines in Development
    2017 Immuno-Oncology Medicines in Development Adoptive Cell Therapies Drug Name Organization Indication Development Phase ACTR087 + rituximab Unum Therapeutics B-cell lymphoma Phase I (antibody-coupled T-cell receptor Cambridge, MA www.unumrx.com immunotherapy + rituximab) AFP TCR Adaptimmune liver Phase I (T-cell receptor cell therapy) Philadelphia, PA www.adaptimmune.com anti-BCMA CAR-T cell therapy Juno Therapeutics multiple myeloma Phase I Seattle, WA www.junotherapeutics.com Memorial Sloan Kettering New York, NY anti-CD19 "armored" CAR-T Juno Therapeutics recurrent/relapsed chronic Phase I cell therapy Seattle, WA lymphocytic leukemia (CLL) www.junotherapeutics.com Memorial Sloan Kettering New York, NY anti-CD19 CAR-T cell therapy Intrexon B-cell malignancies Phase I Germantown, MD www.dna.com ZIOPHARM Oncology www.ziopharm.com Boston, MA anti-CD19 CAR-T cell therapy Kite Pharma hematological malignancies Phase I (second generation) Santa Monica, CA www.kitepharma.com National Cancer Institute Bethesda, MD Medicines in Development: Immuno-Oncology 1 Adoptive Cell Therapies Drug Name Organization Indication Development Phase anti-CEA CAR-T therapy Sorrento Therapeutics liver metastases Phase I San Diego, CA www.sorrentotherapeutics.com TNK Therapeutics San Diego, CA anti-PSMA CAR-T cell therapy TNK Therapeutics cancer Phase I San Diego, CA www.sorrentotherapeutics.com Sorrento Therapeutics San Diego, CA ATA520 Atara Biotherapeutics multiple myeloma, Phase I (WT1-specific T lymphocyte South San Francisco, CA plasma cell leukemia www.atarabio.com
    [Show full text]
  • Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories
    bioRxiv preprint doi: https://doi.org/10.1101/572958; this version posted March 10, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Title: Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories. Authors: Konrad Krawczyk1*, Matthew Raybould2, Aleksandr Kovaltsuk2, Charlotte M. Deane2 1 NaturalAntibody, Hamburg, Germany 2 Oxford University Department of Statistics, Oxford, UK *Correspondence to [email protected] Abstract: Recently it has become possible to query the great diversity of natural antibody repertoires using Next Generation Sequencing (NGS). These methods are capable of producing millions of sequences in a single experiment. Here we compare Clinical Stage Therapeutic antibodies to the ~1b sequences from 60 independent sequencing studies in the Observed Antibody Space Database. Of the 242 post Phase I antibodies, we find 16 with sequence identity matches of 95% or better for both heavy and light chains. There are also 54 perfect matches to therapeutic CDR-H3 regions in the NGS outputs, suggesting a nontrivial amount of convergence between naturally observed sequences and those developed artificially. This has potential implications for both the discovery of antibody therapeutics and the legal protection of commercial antibodies. Introduction Antibodies are proteins in jawed vertebrates that recognize noxious molecules (antigens) for elimination. An organism expresses millions of diverse antibodies to increase the chances that some of them will be able to bind the foreign antigen, initiating the adaptive immune response.
    [Show full text]
  • The Two Tontti Tudiul Lui Hi Ha Unit
    THETWO TONTTI USTUDIUL 20170267753A1 LUI HI HA UNIT ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2017 /0267753 A1 Ehrenpreis (43 ) Pub . Date : Sep . 21 , 2017 ( 54 ) COMBINATION THERAPY FOR (52 ) U .S . CI. CO - ADMINISTRATION OF MONOCLONAL CPC .. .. CO7K 16 / 241 ( 2013 .01 ) ; A61K 39 / 3955 ANTIBODIES ( 2013 .01 ) ; A61K 31 /4706 ( 2013 .01 ) ; A61K 31 / 165 ( 2013 .01 ) ; CO7K 2317 /21 (2013 . 01 ) ; (71 ) Applicant: Eli D Ehrenpreis , Skokie , IL (US ) CO7K 2317/ 24 ( 2013. 01 ) ; A61K 2039/ 505 ( 2013 .01 ) (72 ) Inventor : Eli D Ehrenpreis, Skokie , IL (US ) (57 ) ABSTRACT Disclosed are methods for enhancing the efficacy of mono (21 ) Appl. No. : 15 /605 ,212 clonal antibody therapy , which entails co - administering a therapeutic monoclonal antibody , or a functional fragment (22 ) Filed : May 25 , 2017 thereof, and an effective amount of colchicine or hydroxy chloroquine , or a combination thereof, to a patient in need Related U . S . Application Data thereof . Also disclosed are methods of prolonging or increasing the time a monoclonal antibody remains in the (63 ) Continuation - in - part of application No . 14 / 947 , 193 , circulation of a patient, which entails co - administering a filed on Nov. 20 , 2015 . therapeutic monoclonal antibody , or a functional fragment ( 60 ) Provisional application No . 62/ 082, 682 , filed on Nov . of the monoclonal antibody , and an effective amount of 21 , 2014 . colchicine or hydroxychloroquine , or a combination thereof, to a patient in need thereof, wherein the time themonoclonal antibody remains in the circulation ( e . g . , blood serum ) of the Publication Classification patient is increased relative to the same regimen of admin (51 ) Int .
    [Show full text]
  • Ep 3178848 A1
    (19) TZZ¥__T (11) EP 3 178 848 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 14.06.2017 Bulletin 2017/24 C07K 16/28 (2006.01) A61K 39/395 (2006.01) C07K 16/30 (2006.01) (21) Application number: 15198715.3 (22) Date of filing: 09.12.2015 (84) Designated Contracting States: (72) Inventor: The designation of the inventor has not AL AT BE BG CH CY CZ DE DK EE ES FI FR GB yet been filed GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR (74) Representative: Cueni, Leah Noëmi et al Designated Extension States: F. Hoffmann-La Roche AG BA ME Patent Department Designated Validation States: Grenzacherstrasse 124 MA MD 4070 Basel (CH) (71) Applicant: F. Hoffmann-La Roche AG 4070 Basel (CH) (54) TYPE II ANTI-CD20 ANTIBODY FOR REDUCING FORMATION OF ANTI-DRUG ANTIBODIES (57) The present invention relates to methods of treating a disease, and methods for reduction of the formation of anti-drug antibodies (ADAs) in response to the administration of a therapeutic agent comprising administration of a Type II anti-CD20 antibody, e.g. obinutuzumab, to the subject prior to administration of the therapeutic agent. EP 3 178 848 A1 Printed by Jouve, 75001 PARIS (FR) EP 3 178 848 A1 Description Field of the Invention 5 [0001] The present invention relates to methods of treating a disease, and methods for reduction of the formation of anti-drug antibodies (ADAs) in response to the administration of a therapeutic agent.
    [Show full text]
  • Orphan Drug Designation List
    Orphan Drug Designations and Approvals List as of 09‐01‐2015 Governs October 1, 2015 ‐ December 31, 2015 Row Contact Generic Name Trade Name Designation Date Designation Num Company/Sponsor 1 (‐)‐(3aR,4S,7aR)‐4‐Hydroxy‐4‐ m‐tolylethynyl‐octahydro‐ Novartis indole‐1‐carboxylic acid Pharmaceuticals methyl ester n/a 10/12/2011 Treatment of Fragile X syndrome Corp. 2 (1‐methyl‐2‐nitro‐1H‐ imidazole‐5‐yl)methyl N,N'‐ bis(2‐broethyl) diamidophosphate n/a 6/5/2013 Treatment of pancreatic cancer EMD Serono 3 (1‐methyl‐2‐nitro‐1H‐ imidazole‐5‐yl)methyl N,N'‐ bis(2‐bromoethyl) Threshold diamidophosphate n/a 3/9/2012 Treatment of soft tissue sarcoma Pharmaceuticals, Inc. 4 (1OR)‐7‐amino‐12‐fluoro‐ 2,10,16‐trimethyl‐15 oxo‐ 10,15,16,17‐tetrahydro‐2H‐8,4‐ Treatment of anaplastic (metheno)pyrazolo[4,3‐ lymphoma kinase (ALK)‐positive h][2,5,11]benzoxadiazacyclote or ROS1‐positive non‐small cell tradecine‐3‐carbonitrile n/a 6/23/2015 lung cancer Pfizer, Inc. 5 (1R,3R,4R,5S)‐3‐O‐[2‐O‐ Treatment of vaso‐occlusive benzoyl‐3‐O‐(sodium(2S)‐3‐ crisis in patients with sickle cell cyclohexyl‐propanoate‐ n/a 2/17/2009 disease. Pfizer, Inc. 6 (1S)‐1‐(9‐deazahypoxanthin‐9‐ yl)‐1,4‐dideoxy‐1,4‐imino‐D‐ Treatment of acute Mundipharma ribitol‐hydrochloride n/a 8/13/2004 lymphoblastic leukemia Research Limited Page 1 of 359 Orphan Drug Designations and Approvals List as of 09‐01‐2015 Governs October 1, 2015 ‐ December 31, 2015 Row Contact Generic Name Trade Name Designation Date Designation Num Company/Sponsor 7 Treatment of chronic lymphocytic leukemia and related leukemias to include (1S)‐1‐(9‐deazahypoxanthin‐9‐ prolymphocytic leukemia, adult T‐ yl)‐1,4‐dideoxy‐1,4‐imino‐D‐ cell leukemia, and hairy cell Mundipharma ribitol‐hydrochloride n/a 8/10/2004 leukemia Research Ltd.
    [Show full text]
  • Pre-Clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1
    SOHO Supplement 2015 Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1 Michael Y. Choi,1 George F. Widhopf II,1 Christina C.N. Wu,1 Bing Cui,1 Fitzgerald Lao,1 Anil Sadarangani,1,2 Joy Cavagnaro,3 Charles Prussak,1 Dennis A. Carson,1 Catriona Jamieson,1,2 Thomas J. Kipps1 Abstract Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is an oncoembryonic antigen. Because of its expression on the cell surface of leukemia cells from patients with chronic lymphocytic leukemia (CLL), but not on normal B-cells or other postpartum tissues, ROR1 is an attractive candidate for targeted therapies. UC-961 is a first-in-class humanized monoclonal antibody that binds the extracellular domain of ROR1. In this article we outline some of the preclinical studies leading to an investigational new drug designation, enabling clinical studies in patients with CLL. Clinical Lymphoma, Myeloma & Leukemia, Vol. 15, No. S1, S167-9 ª 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/) Keywords: AKT, cancer stem cell, Cirmtuzumab, CLL, Wnt receptor Receptor Tyrosine Kinase-Like normal B lymphocytes.5,6 Analysis of autoantibodies produced Orphan Receptor 1 Is an by patients immunized with autologous leukemia cells transduced Oncoembryonic Antigen Not to express CD154 identified that these autoantibodies recognized Expressed by Normal Postpartum ROR1 protein on the leukemia cell surface.7 Functional studies Tissues
    [Show full text]
  • Ep 3321281 A1
    (19) TZZ¥¥ _ __T (11) EP 3 321 281 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 16.05.2018 Bulletin 2018/20 C07K 14/79 (2006.01) A61K 38/40 (2006.01) A61K 38/00 (2006.01) A61K 38/17 (2006.01) (2006.01) (2006.01) (21) Application number: 17192980.5 A61K 39/395 A61K 39/44 C07K 16/18 (2006.01) (22) Date of filing: 03.08.2012 (84) Designated Contracting States: • TIAN, Mei Mei AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Coquitlam, BC V3J 7E6 (CA) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO • VITALIS, Timothy PL PT RO RS SE SI SK SM TR Vancouver, BC V6Z 2N1 (CA) (30) Priority: 05.08.2011 US 201161515792 P (74) Representative: Gowshall, Jonathan Vallance Forresters IP LLP (62) Document number(s) of the earlier application(s) in Skygarden accordance with Art. 76 EPC: Erika-Mann-Strasse 11 12746240.6 / 2 739 649 80636 München (DE) (71) Applicant: biOasis Technologies Inc Remarks: Richmond BC V6X 2W8 (CA) •This application was filed on 25.09.2017 as a divisional application to the application mentioned (72) Inventors: under INID code 62. • JEFFERIES, Wilfred •Claims filed after the date of receipt of the divisional South Surrey, BC V4A 2V5 (CA) application (Rule 68(4) EPC). (54) P97 FRAGMENTS WITH TRANSFER ACTIVITY (57) The present invention is related to fragments of duction of the melanotransferrin fragment conjugated to human melanotransferrin (p97). In particular, this inven- a therapeutic or diagnostic agent to a subject.
    [Show full text]